Koshinski Asset Management Inc. Boosts Position in Abbott Laboratories (NYSE:ABT)

Koshinski Asset Management Inc. boosted its position in Abbott Laboratories (NYSE:ABTFree Report) by 0.9% during the 4th quarter, HoldingsChannel reports. The firm owned 24,745 shares of the healthcare product maker’s stock after purchasing an additional 210 shares during the period. Koshinski Asset Management Inc.’s holdings in Abbott Laboratories were worth $2,799,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Intech Investment Management LLC increased its holdings in Abbott Laboratories by 10.0% during the second quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock valued at $3,670,000 after buying an additional 3,200 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Abbott Laboratories by 4.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 479,241 shares of the healthcare product maker’s stock valued at $49,799,000 after acquiring an additional 20,480 shares during the period. Frank Rimerman Advisors LLC increased its stake in shares of Abbott Laboratories by 22,650.7% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 16,608 shares of the healthcare product maker’s stock worth $1,726,000 after purchasing an additional 16,535 shares in the last quarter. 1832 Asset Management L.P. raised its holdings in Abbott Laboratories by 115.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 161,505 shares of the healthcare product maker’s stock worth $16,782,000 after purchasing an additional 86,707 shares during the period. Finally, Epoch Investment Partners Inc. lifted its position in Abbott Laboratories by 1.7% during the second quarter. Epoch Investment Partners Inc. now owns 60,703 shares of the healthcare product maker’s stock valued at $6,308,000 after purchasing an additional 988 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 0.4 %

Shares of ABT stock opened at $113.45 on Tuesday. The stock’s 50-day moving average price is $114.93 and its 200-day moving average price is $112.87. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $121.64. The stock has a market capitalization of $196.78 billion, a price-to-earnings ratio of 34.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 2.08%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is 66.87%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABT. Jefferies Financial Group raised their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Piper Sandler raised their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Sanford C. Bernstein increased their price objective on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 17th. Finally, Royal Bank of Canada upped their target price on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $131.57.

View Our Latest Analysis on ABT

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.